NCT01428479 - Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2011

Primary Completion Date

April 4, 2011

Study Completion Date

April 4, 2011

Conditions

Influenza, Human

Interventions

DRUG

GR121167 Solution

GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg

DRUG

Placebo

Placebo solution will be administered intravenously.

Trial Locations (1)

160-0017

GSK Investigational Site, Tokyo